Found 79 Chemotherapy trials
A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
EA5163/S1709 INSIGNA: A Randomized Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNaturedriven Analysis
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it …
A Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with …
UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
UPCC 11222: A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
The purpose of this study is to test the safety and effectiveness of domvanalimab when given together with zimberelimab with and without chemotherapy. We would like to rely on WCG the IRB of record for this study.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence
This is a study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
UPCC 05418: A Multicenter Double-Blind Randomized Placebo-Controlled Phase III Study of Idasanutlin an MDM2 Antagonist with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.
UPCC 57418: A Phase III Multicenter Randomized Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
This is a study of the effectiveness and safety of giving the experimental drug, APR-246, together with the drug azacitidine to patients with MDS that has not yet been treated with chemotherapy or hypomethylating agents like azacitidine, compared with just giving azacitidine alone.
Please choose between Voice or SMS based delivery of verification code
or